Microscopic kinetics and energetics distinguish GABAA receptor agonists from antagonists

被引:76
|
作者
Jones, MV
Jonas, P
Sahara, Y
Westbrook, GL
机构
[1] Univ Wisconsin, Dept Physiol, Madison, WI 53706 USA
[2] Tokyo Med & Dent Univ, Dept Maxillofacial Biol, Tokyo 113, Japan
[3] Univ Freiburg, Inst Physiol, D-79104 Freiburg, Germany
[4] Oregon Hlth & Sci Univ, Vollum Inst, Portland, OR 97201 USA
[5] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA
关键词
D O I
10.1016/S0006-3495(01)75909-7
中图分类号
Q6 [生物物理学];
学科分类号
071011 ;
摘要
Although agonists and competitive antagonists presumably occupy overlapping binding sites on ligand-gated channels, these interactions cannot be identical because agonists cause channel opening whereas antagonists do not. One explanation is that only agonist binding performs enough work on the receptor to cause the conformational changes that lead to gating. This idea is supported by agonist binding rates at GABAA and nicotinic acetylcholine receptors that are slower than expected for a diffusion-limited process, suggesting that agonist binding involves an energy-requiring event. This hypothesis predicts that competitive antagonist binding should require less activation energy than agonist binding. To test this idea, we developed a novel eleconvolution-based method to compare binding and unbinding kinetics of GABAA receptor agonists and antagonists in outside-out patches from rat hippocampal neurons. Agonist and antagonist unbinding rates were steeply correlated with affinity. Unlike the agonists, three of the four antagonists tested had binding rates that were fast, independent of affinity, and could be accounted for by diffusion- and dehydration-limited processes. In contrast, agonist binding involved additional energy-requiring steps, consistent with the idea that channel gating is initiated by agonist-triggered movements within the ligand binding site. Antagonist binding does not appear to produce such movements, and may in fact prevent them.
引用
收藏
页码:2660 / 2670
页数:11
相关论文
共 50 条
  • [21] Vitamin D receptor antagonists from agonists: An unexpected discovery
    Gleason, James L.
    White, John H.
    Lamblin, Marc
    Wang, Tian-Tian
    Spingarn, Russell
    Burger, Melanie
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2009, 237
  • [23] Repurposing of a Nucleoside Scaffold from Adenosine Receptor Agonists to Opioid Receptor Antagonists
    Tosh, Dilip K.
    Ciancetta, Antonella
    Mannes, Philip
    Warnick, Eugene
    Janowsky, Aaron
    Eshleman, Amy J.
    Gizewski, Elizabeth
    Brust, Tarsis F.
    Bohn, Laura M.
    Auchampach, John A.
    Gao, Zhan-Guo
    Jacobson, Kenneth A.
    ACS OMEGA, 2018, 3 (10): : 12658 - 12678
  • [24] Selective muscarinic receptor agonists and antagonists
    Eglen, RM
    Watson, N
    PHARMACOLOGY & TOXICOLOGY, 1996, 78 (02): : 59 - 68
  • [25] Update in TSH Receptor Agonists and Antagonists
    Gershengorn, Marvin C.
    Neumann, Susanne
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2012, 97 (12): : 4287 - 4292
  • [26] Pharmacology of cannabinoid receptor agonists and antagonists
    Xiang, JN
    Lee, JC
    ANNUAL REPORTS IN MEDICINAL CHEMISTRY, VOL 34, 1999, 34 : 199 - 208
  • [27] Advances in Vasopressin Receptor Agonists and Antagonists
    Ryckmans, Thomas
    ANNUAL REPORTS IN MEDICINAL CHEMISTRY, VOL 44, 2009, 44 : 129 - 147
  • [28] Neurotensin receptor agonists and antagonists for schizophrenia
    Richelson, E
    Fredrickson, PA
    Boules, MM
    AMERICAN JOURNAL OF PSYCHIATRY, 2005, 162 (03): : 633 - 634
  • [29] Designing peptide receptor agonists and antagonists
    Victor J. Hruby
    Nature Reviews Drug Discovery, 2002, 1 : 847 - 858
  • [30] Designing peptide receptor agonists and antagonists
    Hruby, VJ
    NATURE REVIEWS DRUG DISCOVERY, 2002, 1 (11) : 847 - 858